Controversies in the treatment of atherosclerosis include uncertainty about the benefits of fibric acid derivatives, whether inhibition of cholesterol ester transfer protein is helpful or harmful, and about the benefits of statins in patients with renal failure. Key studies in 2010 contributed to the resolution of these long-standing controversies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1563–1574 (2010).
Cannon, C. P. et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N. Engl. J. Med. doi:10.1056/NEJMoa1009744.
Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am. Heart J. 160, 785–794 (2010).
Frick, M. H. et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 317, 1237–1245 (1987).
Rubins, H. B. et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. N. Engl. J. Med. 341, 410–418 (1999).
Keech, A. et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9,795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366, 1849–1861 (2005).
Brousseau, M. E. et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N. Engl. J. Med. 350, 1505–1515 (2004).
Hirano, K. et al. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler. Thromb. Vasc. Biol. 17, 1053–1059 (1997).
Barter, P. J. et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109–2122 (2007).
Baigent, C. & Landry, M. Study of Heart and Renal Protection (SHARP). Kidney Int. Suppl. 84, S207–S210 (2003).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
S. E. Nissen declares that the Cleveland Clinic Center for Clinical Research has received funding to perform clinical trials from Astra Zeneca, Daiichi-Sankyo, Eli Lilly, Karo Bio, Novartis, Novo Nordisk, Roche, Pfizer, Resverlogix, Sanofi-Aventis, and Takeda. Dr. Nissen is involved in these clinical trials, but receives no personal remuneration for his participation. Dr Nissen consults for many pharmaceutical companies, but requires them to donate all honoraria or consulting fees directly to charity so that he receives neither income nor a tax deduction.
Rights and permissions
About this article
Cite this article
Nissen, S. New therapeutic insights. Nat Rev Cardiol 8, 70–72 (2011). https://doi.org/10.1038/nrcardio.2010.208
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2010.208
